Chinese OINDP developer CF PharmTech announced that it has completed a $50 million Series F financing round approximately six months after completing a $90 million financing round. Investors participating in the latest financing include BioTrack Capital, CICC Qichen, CICC Qide, SAIC Hengxu, GP M&A Fund, and Watson Investment, as well as existing investors Passion Capital and Yuanming Capital.
The company said, “With this new round of funding, CF Pharmtech is more poised than ever to provide respiratory disease treatments for China and global market.”
Read the CF Pharmtech press release.
